The Role of Caffeine in Neurodegenerative Diseases: Possible Genetic and Cellular Signaling Mechanisms

Bioactive Nutraceuticals and Dietary Supplements in Neurological and Brain Disease: Prevention and Therapy

Volumn , Issue , 2014, Pages 261-279

  Vinh quôc Lu'o'ng, Khanh ^a   Thi Hoàng Nguyên, Lan ^a  

^a Vietnamese American Medical Research Foundation   (United States)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Caffeine; Coffee; Neurodegenerative diseases; Parkinson's disease

Indexed keywords

EID: 84942683582     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-411462-3.00028-X     Document Type: Chapter

References (276)

1. Abeti R., Abramov A.Y., Duchen M.R. β-amyloid activates PARP causing astrocytic metabolic failure and neuronal death. Brain 2011, 134:1658-1672.
2. Aguiar L.M., Nobre H.V., Macêdo D.S., Oliveira A.A., Freitas R.M., et al. Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats. Pharmacol. Biochem. Behav. 2006, 84:415-419.
3. Ahmed H.H. Modulatory effects of vitamin E, acetyl-L-carnitine and alpha-lipoic acid on new potential biomarkers for Alzheimer's disease in rat model 2012, 64:549-556.
4. Amtul Z., Uhrig M., Wang L., Rozmahel R.F., Beyreuther K. Detrimental effects of arachidonic acid and its metabolites in cellular and mouse models of Alzheimer's disease: structural insight. Neurobiol. Aging 2012, 33(831):e21-e31.
5. Anand A., Gupta P.K., Sharma N.K., Prabhakar S. Soluble VEGFR1 (sVEGFR1) as a novel marker of amyotrophic lateral sclerosis (ALS) in the North Indian ALS patients. Eur. J. Neurol. 2012, 19:788-792.
6. Andreadou E., Kapaki E., Kokotis P., Paraskevas G.P., Katsaros N., et al. Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis. Vivo 2008, 22:137-141.
7. Andreassen O.A., Dedeoglu A., Friedlich A., Ferrante K.L., Hughes D., et al. Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice. Exp. Neurol. 2001, 168:419-424.
8. Alhaider I.A., Aleisa A.M., Tran T.T., Alkadhi K.A. Sleep deprivation prevents stimulation-induced increases of levels of P-CREB and BDNF: protection by caffeine. Mol. Cell Neurosci. 2011, 46:742-751.
9. Almer G., Teismann P., Stevic Z., Halaschek-Wiener J., Deecke L., et al. Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology 2002, 58:1277-1279.
10. Alves S., Régulier E., Nascimento-Ferreira I., Hassig R., Dufour N., et al. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease. Hum. Mol. Genet. 2008, 17:2071-2083.
11. Alzoubi K.H., Srivareerat M., Aleisa A.M., Alkadhi K.A. Chronic caffeine treatment prevents stress-induced LTP impairment: the critical role of phosphorylated CaMKII and BDNF. J. Mol. Neurosci. 2013, 49:11-20.
12. Aubby D., Saggu H.K., Jenner P., Quinn N.P., Harding A.E., Marsden C.D. Leukocyte glutamate dehydrogenase activity in patients with degenerative neurological disorders. J. Neurol. Neurosurg. Psychiatry 1988, 51:893-902.
13. Araujo J., Breuer P., Dieringer S., Krauss S., Dorn S., et al. FOXO4-dependent upregulation of superoxide dismutase-2 in response to oxidative stress is impaired in spinocerebellar ataxia type 3. Hum. Mol. Genet. 2011, 20:2928-2941.
14. Baba A., Mitsumori K., Yamada M.K., Nishiyama N., Matsuki N., Ikegaya Y. Beta-amyloid prevents excitotoxicity via recruitment of glial glutamate transporters. Naunyn. Schmiedebergs. Arch. Pharmacol 2003, 368(3):234-238.
15. Bademci G., Edwards T.L., Torres A.L., Scott W.K., Züchner S., et al. A rare novel deletion of the tyrosine hydroxylase gene in Parkinson disease. Hum. Mutat. 2010, 31:E1767-E1771.
16. Bagh M.B., Maiti A.K., Jana S., Banerjee K., Roy A., Chakrabarti S. Quinone and oxyradical scavenging properties of N-acetylcysteine prevent dopamine mediated inhibition of Na+, K+-ATPase and mitochondrial electron transport chain activity in rat brain: implications in the neuroprotective therapy of Parkinson's disease. Free Radic. Res. 2008, 42:574-581.
17. Bains J.S., Shaw C.A. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res. Rev. 1997, 25:335-358.
18. Bairam A., Kinkead R., Lajeunesse Y., Joseph V. Neonatal caffeine treatment does not induce long-term consequences on TrkB receptors or BDNF expression in chemosensory organs of adult rats. Neurosci. Lett. 2010, 468:292-296.
19. Barcia C., Bautista V., Sánchez-Bahillo A., Fernández-Villalba E., et al. Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian. J. Neural. Transm. 2005, 112:1237-1348.
20. Bassini A., Magalhães-Neto A.M., Sweet E., Bottino A., Veiga C., et al. Caffeine decreases systemic urea in elite soccer players during intermittent exercise. Med. Sci. Sports Exerc. 2013, 45:683-690.
21. Beck M., Flachenecker P., Magnus T., Giess R., Reiners K., et al. Autonomic dysfunction in ALS: a preliminary study on the effects of intrathecal BDNF. Amyotroph. Lateral Scler. Other Motor Neuron. Disord. 2005, 6:100-103.
22. Beghi E., Pupillo E., Messina P., Giussani G., Chiò A., et al. Coffee and amyotrophic lateral sclerosis: a possible preventive role. Am. J. Epidemiol. 2011, 174:1002-1008.
23. Bell K.F., Ducatenzeiler A., Ribeiro-da-Silva A., Duff K., Bennett D.A., Cuello A.C. The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiol. Aging 2006, 27(11):1644-1657.
24. Bendotti C., Atzori C., Piva R., Tortarolo M., Strong M.J., et al. Activated p38MAPK is a novel component of the intracellular inclusions found in human amyotrophic lateral sclerosis and mutant SOD1 transgenic mice. J. Neuropathol. Exp. Neurol. 2004, 63:113-119.
25. Blanco A., Alvarez S., Fresno M., Muñoz-Fernández M.A. Amyloid-β induces cyclooxygenase-2 and PGE2 release in human astrocytes in NF-κ B dependent manner. J. Alzheimers. Dis 2010, 22:493-505.
26. Bos I.W., Hoogland G., Meine Jansen C.F., Willigen G., et al. Increased glutamine synthetase but normal EAAT2 expression in platelets of ALS patients. Neurochem. Int. 2006, 48:306-311.
27. Boucherie C., Schäfer S., Lavand'homme P., Maloteaux J.M., Hermans E. Chimerization of astroglial population in the lumbar spinal cord after mesenchymal stem cell transplantation prolongs survival in a rat model of amyotrophic lateral sclerosis. J. Neurosci. Res. 2009, 87:2034-2046.
28. Bramblett G.T., Goedert M., Jakes R., Merrick S.E., Trojanowski J.Q., Lee V.M.Y. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 1993, 10:1089-1099.
29. Brashear A., Mink J.W., Hill D.F., Boggs N., McCall W.V., et al. ATP1A3 mutations in infants: a new rapid-onset dystonia-Parkinsonism phenotype characterized by motor delay and ataxia. Dev. Med. Child. Neurol 2012, 54:1065-1067.
30. Brothers H.M., Marchalant Y., Wenk G.L. Caffeine attenuates lipopolysaccharide-induced neuroinflammation. Neurosci. Lett. 2010, 480:97-100.
31. Butterfield D.A., Howard B., Yatin S., Koppal T., Drake J., et al. Elevated oxidative stress in models of normal brain aging and Alzheimer's disease. Life Sci. 1999, 65:1883-1892.
32. Cannon S.C. Paying the price at the pump: dystonia from mutations in a Na+/K+-ATPase. Neuron 2004, 43:153-154.
33. Cao C., Cirrito J.R., Lin X., Wang L., Verges D.K., et al. Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice. J. Alzheimers Dis. 2009, 17:681-697.
34. Cao C., Loewenstein D.A., Lin X., Zhang C., Wang L., et al. High blood caffeine levels in MCI linked to lack of progression to dementia. J. Alzheimers Dis. 2012, 30:559-572.
35. Carilho R., de Carvalho M., Swash M., Pinto S., Pinto A., Costa J. Vascular endothelial growth factor and amyotrophic lateral sclerosis: The Interplay with exercise and non-invasive ventilation. Muscle Nerve 2013 Jul 19, (Epub ahead of print). 10.1002/mus.23955.
36. Carrasco E., Casper D., Werner P. PGE2 receptor EP1 renders dopaminergic neurons selectively vulnerable to low-level oxidative stress and direct PGE2 neurotoxicity. J. Neurosci. Res. 2007, 85:3109-3117.
37. Chauhan N.B., Lee J.M., Siegel G.J. Na,K-ATPase mRNA levels and plaque load in Alzheimer's disease. J. Mol. Neurosci. 1997, 9:151-166.
38. Chen D., Shen L., Wang L., Lu A., Zhang H., et al. Association of polymorphisms in vascular endothelial growth factor gene with the age of onset of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2007, 8:144-149.
39. Chen H., Zhang S.M., Hernan M.A., Schwatzschild M.A., Willet W.C., et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 2003, 60:1059-1064.
40. Chen L., Wang Y., Xiao H., Wang L., Wang C., et al. The 712A/G polymorphism of brain-derived neurotrophic factor is associated with Parkinson's disease but not major depressive disorder in a Chinese Han population. Biochem. Biophys. Res. Comm. 2011, 408:318-321.
41. Chen X., Lan X., Roche I., Liu R., Geiger J.D. Caffeine protects against MPTP-induced blood-brain barrier dysfunction in mouse striatum. J. Neurochem. 2008, 107:1147-1157.
42. Chi L., Ke Y., Luo C., Gozal D., Liu R. Depletion of reduced glutathione enhances motor neuron degeneration in vitro and in vivo. Neuroscience 2007, 144:991-1003.
43. Chiappelli M., Borroni B., Archetti S., Calabrese E., Corsi M.M., et al. VEGF gene and phenotype relation with Alzheimer's disease and mild cognitive impairment. Rejuvenation Res. 2006, 9:485-493.
44. Chiba-Falek O., Kowalak J.A., Smulson M.E., Nussbaum R.L. Regulation of alphasynuclein expression by poly (ADP ribose) polymerase-1 (PARP-1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene. Am. J. Hum. Genet. 2005, 76:478-492.
45. Choi J.-K., Küstermann E., Dedeoglu A., Jenkins B.G. Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation. Eur. J. Neurosci. 2009, 30:2143-2150.
46. Choi J.-M., Hong J.-H., Chae M.-J., Hung N.P., Kang H.-S., et al. Analysis of mutations and the association between polymorphisms in the cerebral dopamine neurotrophic factor (CDNF) gene and Parkinson disease. Neurosci. Lett. 2011, 493:97-101.
47. Chung Y.H., Joo K.M., Lee Y.J., Shin D.H., Cha C.I. Reactive astrocytes express PARP in the central nervous system of SODG93A transgenic mice. Brain Res. 2004, 1003:199-204.
48. Ciaramella A., Salani F., Bizzoni F., Orfei M.D., Langella R., et al. The stimulation of dendritic cells by amyloid beta 1-42 reduces BDNF production in Alzheimer's disease patients. Brain Behav. Immun. 2013, 32:29-32.
49. Cifuentes F., González C.E., Fiordelisio T., Guerrero G., Lai F.A., Hernández-Cruz A. A ryanodine fluorescent derivative reveals the presence of high-affinity ryanodine binding sites in the Golgi complex of rat sympathetic neurons, with possible functional roles in intracellular Ca2+ signaling. Cell. Signal. 2001, 13:353-362.
50. Cleaver J.E., Banda M.J., Troll W., Borek C. Some protease inhibitors are also inhibitors of poly(ADP-ribose) polymerase. Carcinogenesis 1986, 7:323-325.
51. Costa M.S., Botton P.H., Mioranzza S., Ardais A.P., Moreira J.D., et al. Caffeine improves adult mice performance in the object recognition task and increases BDNF and TrkB independent on phospho-CREB immunocontent in the hippocampus. Neurochem. Int. 2008, 53:89-94.
52. Costa M.S., Botton P.H., Mioranzza S., Souza D.O., Porciúncula L.O. Caffeine prevents age-associated recognition memory decline and changes brain-derived neurotrophic factor and tirosine kinase receptor (TrkB) content in mice. Neuroscience 2008, 153:1071-1078.
53. Côté S., Carmichael P.H., Verreault R., Lindsay J., Lefebvre J., Laurin D. Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer's disease. Alzheimers Dement 2012, 8:219-226.
54. Dagda R.K., Zhu J., Kulich S.M., Chu C.T. Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress: implications for Parkinson's disease. Autophagy 2008, 4:770-782.
55. Datta U., Noailles P.A., Rodriguez M., Kraft M., Zhang Y., Angulo J.A. Accumulation of tyrosine hydroxylase messenger RNA molecules in the rat mesencephalon by chronic caffeine treatment. Neurosci. Lett. 1996, 220:77-80.
56. de Carvalho M., Marcelino E., de Mendonça A. Electrophysiological studies in healthy subjects involving caffeine. J. Alzheimers Dis. 2010, 20:S63-S69.
57. de Carvalho Aguiar P., Sweadner K.J., Penniston J.T., Zaremba J., Liu L., et al. Mutations in the Na+/K+-ATPase α3 gene ATP1A3 are associated with rapid-onset dystonia parkinsonism. Neuron 2004, 43:169-175.
58. de la Monte S.M., Ganju N., Feroz N., Luong T., Banerjee K., et al. Oxygen free radical injury is sufficient to cause some Alzheimer-type molecular abnormalities in human CNS neuronal cells. J. Alzheimers Dis 2000, 2:261-281.
59. Deng Y., Xu Z., Xu B., Tian Y., Xin X., et al. The protective effect of riluzole on manganese caused disruption of glutamate-glutamine cycle in rats. Brain Res. 2009, 1289:106-117.
60. Del Bo R., Ghezzi S., Scarlato M., Albani D., Galimberti D., et al. Role of VEGF gene variability in longevity: a lesson from the Italian population. Neurobiol. Aging 2008, 29:1917-1922.
61. Del Bo R., Scarlato M., Ghezzi S., Martinelli Boneschi F., et al. Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol. 2005, 57:373-380.
62. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Lees A., et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 1989, 52:381-389.
63. Dexter D.T., Holley A.E., Flitter W.D., Slater T.F., Wells S.R., Daniel S.E., et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 1994, 9:92-97.
64. Dewil M., de la Cruz V.F., Van Den Bosch L., Robberecht W. Inhibition of p38 mitogen activated protein kinase activation and mutant SOD1G93A-induced motor neuron death. Neurobiol. Dis. 2007, 26:332-341.
65. Dickey C.A., Gordon M.N., Wilcock D.M., Herber D.L., Freeman M.J., Morgan D. Dysregulation of Na+/K+ ATPase by amyloid in APP+PS1 transgenic mice. BMC Neurosci. 2005, 6:7.
66. Dobretsov M., Stimers J.R. Neuronal function and α3 isoform of the Na/K-ATPase. Front. Biosci 2005, 10:2373-2396.
67. Drachman D.B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 2002, 52:771-778.
68. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003, 112:257-269.
69. Eliasson M.J., Sampei K., Mandir A.S., Hurn P.D., Traystman R.J., et al. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat. Med. 1997, 3:1089-1095.
70. Ellis D.Z., Rabe J., Sweadner K.J. Global loss of Na,K-ATPase and its nitric oxide-mediated regulation in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. 2003, 23:43-51.
71. Falk T., Zhang S., Sherman S.J. Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease. Mol. Neurodegener. 2009, 4:49.
72. Fehér A., Juhász A., Rimanóczy A., Kálmán J., Janka Z. Association study of interferon-γ, cytosolic phospholipase A2, and cyclooxygenase-2 gene polymorphisms in Alzheimer disease. Am. J. Geriatr. Psychiatry. 2010, 18:983-987.
73. Feoktistov I., Goldstein A.E., Ryzhov S., Zeng D., Belardinelli L., et al. Differential expression of adenosine receptors in human endothelial cells: role of A2B receptors in angiogenic factor regulation. Circ. Res. 2002, 90:531-538.
74. Fernández-Santiago R., Sharma M., Mueller J.C., Gohlke H., Illig T., et al. Possible gender-dependent association of vascular endothelial growth factor (VEGF) gene and ALS. Neurology 2006, 66:1929-1931.
75. Ferrarese C., Sala G., Riva R., Begni B., Zoia C., et al. Decreased platelet glutamate uptake in patients with amyotrophic lateral sclerosis. Neurology 2001, 56:270-272.
76. Ferrer I., Blanco R., Carmona M., Puig B. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J. Neural. Transm. 2001, 108:1397-1415.
77. Feve A.P. Tyrosine Hydroxylase and Parkinsons Disease. CNS Neurol Disord Drug Targets 2012, 11:450-455.
78. Fiala M., Lin J., Ringman J., Kermani-Arab V., Tsao G., et al. Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. J. Alzheimers Dis. 2005, 7:221-232.
79. Fiebich B.L., Lieb K., Hüll M., Aicher B., van Ryn J., et al. Effects of caffeine and paracetamol alone or in combination with acetylsalicylic acid on prostaglandin E2 synthesis in rat microglial cells. Neuropharmacology 2000, 39:2205-2213.
80. Figlewicz D.P., Evans S.B., Murphy J., Hoen M., Baskin D.G. Expression of receptors for insulin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat. Brain Res. 2003, 964:107-115.
81. Fisone G., Borgkvist A., Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol. Life Sci. 2004, 61:857-872.
82. Flanagan S.W., Anderson R.D., Ross M.A., Oberley L.W. Overexpression of manganese superoxide dismutase attenuates neuronal death in human cells expressing mutant (G37R) Cu/Zn-superoxide dismutase. J. Neurochem. 2002, 81:170-177.
83. Fu Y.J., Xiong S., Lovell M.A., Lynn B.C. Quantitative proteomic analysis of mitochondria in aging PS-1 transgenic mice. Cell Mol. Neurobiol. 2009, 29:649-664.
84. Furukawa Y., Graf W.D., Wong H., Shimadzu M., Kish S.J. Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations. Neurology 2001, 56:260-263.
85. Garbayo E., Ansorena E., Lanciego J.L., Blanco-Prieto M.J., Aymerich M.S. Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease. Mov. Disord. 2011, 26:1943-1947.
86. Geraets L., Moonen H.J., Wouters E.F., Bast A., Hageman G.J. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations. Biochem. Pharmacol. 2006, 72:902-910.
87. Geraets L., Haegens A., Weseler A.R., Brauers K., Vernooy J.H., et al. Inhibition of acute pulmonary and systemic inflammation by 1,7-dimethylxanthine. Eur. J. Pharmacol. 2010, 629:132-139.
88. Gonçalves A., Oliveira C., Ferro M.A., Dinis M., Cunha L. Glutamate dehydrogenase deficiency in Machado-Joseph disease. Can. J. Neurol. Sci. 1993, 20:147-150.
89. Gonçalves N., Simões A.T., Cunha R.A., de Almeida L.P. Caffeine and adenosine A2A receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease. Ann. Neurol. 2013, 73:655-666.
90. Gonzalez Deniselle M.C., López-Costa J.J., Saavedra J.P., Pietranera L., Gonzalez S.L., et al. Progesterone neuroprotection in the Wobbler mouse, a genetic model of spinal cord motor neuron disease. Neurobiol. Dis. 2002, 11:457-468.
91. Gołembiowska K., Dziubina A. The effect of adenosine A2A receptor antagonists on hydroxyl radical, dopamine, and glutamate in the striatum of rats with altered function of VMAT2. Neurotox. Res. 2012, 22:150-157.
92. Grant M.B., Tarnuzzer R.W., Caballero S., Ozeck M.J., Davis M.I., et al. Adenosine receptor activation induces vascular endothelial growth factor in human retinal endothelial cells. Circ Res. 1999, 85:699-706.
93. Greenamyre J.T., MacKenzie G., Peng T.I., Stephans S.E. Mitochondrial dysfunction in Parkinson's disease. Biochem. Soc. Symp. 1999, 66:85-97.
94. Gu J.W., Brady A.L., Anand V., Moore M.C., Kelly W.C., Adair T.H. Adenosine upregulates VEGF expression in cultured myocardial vascular smooth muscle cells. Am. J. Physiol. 1999, 277:H595-H602.
95. Gu Q.B., Zhao J.X., Fei J., Schwarz W. Modulation of Na+,K+ pumping and neurotransmitter uptake by beta-amyloid. Neuroscience 2004, 126:61-67.
96. Gupta P.K., Prabhakar S., Abburi C., Sharma N.K., Anand A. Vascular endothelial growth factor-A and chemokine ligand (CCL2) genes are upregulated in peripheral blood mononuclear cells in Indian amyotrophic lateral sclerosis patients. J. Neuroinflammation 2011, 8:114.
97. Gupta P.K., Prabhakar S., Sharma S., Anand A. A predictive model for amyotrophic lateral sclerosis (ALS) diagnosis. J. Neurol. Sci. 2012, 312:68-72.
98. Han K., Jia N., Li J., Yang L., Min L.Q. Chronic caffeine treatment reverses memory impairment and the expression of brain BNDF and TrkB in the PS1/APP double transgenic mouse model of Alzheimer's disease. Mol. Med. Rep. 2013, 8:737-740.
99. Hariri A.R., Goldberg T.E., Mattay V.S., Kolachana B.S., Callicott J.H., et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J. Neurosci. 2003, 23:6690-6694.
100. Hattori N., Kitagawa K., Higashida T., Yagyu K., Shimohama S., et al. CI-ATPase and Na+/K(+)-ATPase activities in Alzheimer's disease brains. Neurosci. Lett. 1998, 254:141-144.
101. Hensley K., Floyd R.A., Zheng N.Y., Nael R., Robinson K.A., et al. P38 kinase is activated in the Alzheimer's disease brain. J Neurochem. 1999, 72:2053-2058.
102. Hertz J.M., Ostergaard K., Juncker I., Pedersen S., Romstad A., et al. Low frequency of Parkin, Tyrosine Hydroxylase, and GTP Cyclohydrolase I gene mutations in a Danish population of early-onset Parkinson's Disease. Eur. J. Neurol. 2006, 13:385-390.
103. Hivert B., Cerruti C., Camu W. Hydrogen peroxide-induced motoneuron apoptosis is prevented by poly ADP ribosyl synthetase inhibitors. Neuroreport 1998, 9:1835-1838.
104. Ho L., Pieroni L., Winger D., Purohit D.P., Aisen P.S., Pasinetti G.M. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J. Neurosci. Res. 1999, 57:295-303.
105. Holasek S.S., Wengenack T.M., Kandimalla K.K., Montano C., Gregor D.M., et al. Activation of the stress-activated MAP kinase, p38, but not JNK in cortical motor neurons during early presymptomatic stages of amyotrophic lateral sclerosis in transgenic mice. Brain Res. 2005, 1045:185-198.
106. Honig L.S., Chambliss D.D., Bigio E.H., Carroll S.L., Elliott J.L. Glutamate transporter EAAT2 splice variants occur not only in ASL, but also in AD and controls. Neurology. 2000, 55(8):1082-1088.
107. Howells D.W., Porritt M.J., Wong J.Y., Batchelor P.E., Kalnins R., et al. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp. Neurol. 2000, 166:127-135.
108. Hu G., Bidel S., Jousilahti P., Antikainen R., Tuomilehto J. Coffee and tea consumption and the risk of Parkinson's disease. Mov. Disord. 2007, 22:2242-2248.
109. Iglesias I., León D., Ruiz M.A., Albasanz J.L., Martín M. Chronic intake of caffeine during gestation down regulates metabotropic glutamate receptors in maternal and fetal rat heart. Amino Acids 2006, 30:257-266.
110. Iłzecka J. Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients. Acta Neurol. Scand. 2003, 108:125-129.
111. Iłzecka J. Cerebrospinal fluid vascular endothelial growth factor in patients with amyotrophic lateral sclerosis. Clin. Neurol. Neurosurg. 2004, 106:289-293.
112. Infante J., Llorca J., Mateo I., Rodríguez-Rodríguez E., Sánchez-Quintana C., et al. Interaction between Poly(ADP-Ribose) Polymerase 1 and Interleukin 1A genes is associated with Alzheimer's disease risk. Dement. Geriatr. Cogn. Disord. 2007, 23:215-218.
113. Infante J., Sánchez-Juan P., Mateo I., Rodríguez-Rodríguez E., et al. Poly(ADP-ribose) polymerase-1 (PARP-1) genetic variants are protective against Parkinson's disease. J. Neurol. Sci. 2007, 256:68-70.
114. Iwashita A., Mihara K., Yamazaki S., Matsuura S., Ishida J., et al. A new Poly(ADP-ribose) polymerase inhibitor, FR261529 [2-(4-chlorophenyl)-5-quinoxalinecarboxamide], ameliorates methamphetamine-induced dopaminergic neurotoxicity in mice. J. Pharmacol. Exp. Ther. 2004, 310:1114-1124.
115. Izumi Y., Yamamoto N., Matsuo T., Wakita S., Takeuchi H., et al. Vulnerability to glutamate toxicity of dopaminergic neurons is dependent on endogenous dopamine and MAPK activation. J. Neurochem 2009, 110:745-755.
116. Jacob C.P., Koutsilieri E., Bartl J., et al. Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J. Alzheimers Dis. 2007, 11(1):97-116.
117. Jafari M., Rabbani A. Studies on the mechanism of caffeine action in alveolar macrophages: caffeine elevates cyclic adenosine monophosphate level and prostaglandin synthesis. Metabolism 2004, 53:687-692.
118. Janik-Papis K., Zaras M., Krzyzanowska A., Wozniak K., Blasiak J., et al. Association between vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in a Polish population. Exp. Mol. Pathol. 2009, 87:234-238.
119. Kachroo A., Irizarry M.C., Schwarzschild M.A. Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Exp. Neurol. 2010, 223:657-661.
120. Kajiyama K., Ueno S., Tatsumi T., Yorifuji S., Takahashi M., Tarui S. Decreased glutamate dehydrogenase protein in spinocerebellar degeneration. J. Neurol. Neurosurg. Psychiatry 1988, 51:1078-1080.
121. Kalaria R.N., Cohen D.L., Premkumar D.R., Nag S., LaManna J.C., Lust W.D. Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. Brain Res. Mol. Brain Res. 1998, 62:101-105.
122. Kamphuis D.J., Koelman H., Lees A.J., Tijssen M.A. Sporadic rapid-onset dystonia-parkinsonism presenting as Parkinson's disease. Mov. Disord. 2006, 21:118-119.
123. Kandinov B., Grigoriadis N.C., Touloumi O., Drory V.E., Offen D., Korczyn A.D. Immunohistochemical analysis of sympathetic involvement in the SOD1-G93A transgenic mouse model of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener 2013, 14:424-433.
124. Kang C.H., Jayasooriya R.G., Dilshara M.G., Choi Y.H., Jeong Y.K., et al. Caffeine suppresses lipopolysaccharide-stimulated BV2 microglial cells by suppressing Akt-mediated NF-κB activation and ERK phosphorylation. Food Chem. Toxicol. 2012, 50:4270-4276.
125. Karunakaran S., Ravindranath V. Activation of p38 MAPK in the substantia nigra leads to nuclear translocation of NF-kappaB in MPTP-treated mice: implication in Parkinson's disease. J. Neurochem. 2009, 109:17911-17919.
126. Kassner S.S., Bonaterra G.A., Kaiser E., Hildebrandt W., Metz J., et al. Novel systemic markers for patients with Alzheimer disease? - A pilot study. Cur. Alzheimer Res. 2008, 5:358-366.
127. Kaufmann W.E., Worley P.F., Pegg J., Bremer M., Isakson P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc. Natl. Acad. Sci. U S A 1996, 93:2317-2321.
128. Kauppinen T.M., Suh S.W., Higashi Y., Berman A.E., Escartin C., et al. Poly(ADP-ribose)polymerase-1 modulates microglial responses to amyloid β. J. Neuroinflammation 2011, 8:152.
129. Khan F.H., Sen T., Chakrabarti S. Dopamine oxidation products inhibit Na+-K+-ATPase activity in crude synaptosomal-mitochondrial fraction from rat brain. Free Radic. Res. 2003, 37:597-601.
130. Knott C., Stern G., Wilkin G.P. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol. Cell Neurosci. 2000, 16:724-739.
131. Kiaei M., Kipiani K., Petri S., Choi D.K., Chen J., et al. Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurochem. 2005, 93:403-411.
132. Kim S.H., Henkel J.S., Beers D.R., Sengun I.S., Simpson E.P., et al. PARP expression is increased in astrocytes but decreased in motor neurons in the spinal cord of sporadic ALS patients. J. Neuropathol. Exp. Neurol. 2003, 62:88-103.
133. Kim S.H., Engelhardt J.I., Henkel J.S., Siklós L., Soós J., et al. Widespread increased expression of the DNA repair enzyme PARP in brain in ALS. Neurology 2004, 62:319-322.
134. Kim E.K., Choi E.J. Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys. Acta 2010, 1802:396-405.
135. Kim J., Lee S., Shim J., Kim H.W., Kim J., et al. Caffeinated coffee, decaffeinated coffee, and the phenolic phytochemical chlorogenic acid up-regulate NQO1 expression and prevent H2O2-induced apoptosis in primary cortical neurons. Neurochem. Int. 2012, 60:466-474.
136. Krishnakumar R., Kraus W.L. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol. Cell. 2010, 39:8-24.
137. Kulich S.M., Chu C.T. Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease. J. Neurochem. 2001, 77:1058-1066.
138. Kulich S.M., Horbinski C., Patel M., Chu C.T. 6-Hydroxydopamine induces mitochondrial ERK activation. Free Radic. Biol. Med. 2007, 43:372-383.
139. Kumar A.R., Kurup P.A. Hypothalamic digoxin related membrane Na+-K+-ATPase inhibition and familial basal ganglia calcification. Neurosci. Res. 2002, 42:35-44.
140. Küst B.M., Copray J.C., Brouwer N., Troost D., Boddeke H.W. Elevated levels of neurotrophins in human biceps brachii tissue of amyotrophic lateral sclerosis. Exp. Neurol. 2002, 177:419-427.
141. Ladewig T., Kloppenburg P., Lalley P.M., et al. Spatial profiles of store-dependent calcium release in motoneurones of the nucleus hypoglossus from newborn mouse. J. Physiol. 2003, 547:775-787.
142. Lambrechts D., Poesen K., Fernández-Santiago R., Al-Chalabi A., Del Bo R., et al. Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype. J. Med. Genet. 2009, 46:840-846.
143. Lee J., Ha J.H., Kim S., Oh Y., Kim S.W. Caffeine decreases the expression of Na+/K+-ATPase and the type 3 Na+/H+ exchanger in rat kidney. Clin. Exp. Pharmacol. Physiol. 2002, 29:559-563.
144. Lee K.W., Chen W., Junn E., Im J.Y., Grosso H., et al. Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model. J. Neurosci. 2011, 31:6963-6971.
145. Lee K.W., Im J.Y., Woo J.M., Grosso H., Kim Y.S., et al. Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson's disease. Neurotherapeutics 2013, 10:143-153.
146. Leite M.R., Wilhelm E.A., Jesse C.R., Brandão R., Nogueira C.W. Protective effect of caffeine and a selective A2A receptor antagonist on impairment of memory and oxidative stress of aged rats. Exp. Gerontol. 2011, 46:309-315.
147. León D., Albasanz J.L., Ruíz M.A., Iglesias I., Martín M. Effect of chronic gestational treatment with caffeine or theophylline on Group I metabotropic glutamate receptors in maternal and fetal brain. J. Neurochem. 2005, 94:440-451.
148. Leuner K., Schütt T., Kurz C., Eckert S.H., Schiller C., et al. Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation. Antioxid. Redox. Signal 2012, 16:1421-1433.
149. Li S., Mallory M., Alford M., Tanaka S., Masliah E. Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J. Neuropathol. Exp. Neurol. 1997, 56:901-911.
150. Li Y., Liu L., Barger S.W., Griffin W.S.T. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 2003, 23:1605-1611.
151. Liang X., Wang Q., Shi J., Lokteva L., Breyer R.M., et al. The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann. Neurol. 2008, 64:304-314.
152. Liguri G., Taddei N., Nassi P., Latorraca S., Nediani C., Sorbi S. Changes in Na+,K+-ATPase, Ca2+-ATPase and some soluble enzymes related to energy metabolism in brains of patients with Alzheimer's disease. Neurosci. Lett. 1990, 112:338-342.
153. Lim Y.Y., Villemagne V.L., Laws S.M., Ames D., Pietrzak R.H., et al. BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease. Neurobiol. Aging 2013, 34:2457-2464.
154. Lindsay J., Laurin D., Verreault R., Hébert R., Helliwell B., et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am. J. Epidemiol. 2002, 156:445-453.
155. Liu D., Wen J., Liu J., Li L. The roles of free radicals in amyotrophic lateral sclerosis: reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids. FASEB J. 1999, 13:2318-2328.
156. Liu H.P., Lin W.Y., Wu B.T., Liu S.H., Wang W.F., et al. Evaluation of the poly(ADP-ribose) polymerase-1 gene variants in Alzheimer's disease. J. Clin. Lab. Anal. 2010, 24:182-186.
157. Liu W.H., Chang L.S. Caffeine induces matrix metalloproteinase-2 (MMP-2) and MMP-9 down-regulation in human leukemia U937 cells via Ca2+/ROS-mediated suppression of ERK/c-fos pathway and activation of p38 MAPK/c-jun pathway. J. Cell Physiol. 2010, 224:775-785.
158. López N., Tormo C., De Blas I., Llinares I., Alom J. Oxidative stress in Alzheimer's disease and mild cognitive impairment with high sensitivity and specificity. J. Alzheimers Dis. 2013, 33:823-829.
159. Love S., Barber R., Wilcock G.K. Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimers's disease. Brain 1999, 122:247-253.
160. Luong K., Nguyên L. Environmental factors in Alzheimer's and Parkinson's diseases. J. Alzheimers Dis Parkinsonism 2013, 3:1.
161. Luong K., Nguyên L. Molecular brain. The Role of Vitamin D in Amyotrophic Lateral Scler.Possible Genet. Cell. Signal. Mech. 2013, 6:16.
162. Lynch-Day M.A., Mao K., Wang K., Zhao M., Klionsky D.J. The role of autophagy in Parkinson's disease. Cold Spring Harb. Perspect. Med. 2012, 2. a009357.
163. Lysogorskaia E.V., Abramycheva NIu, Zakharova M.N., Illarioshkin S.N. Association between the VEGF -2578S/A polymorphism and amyotrophic lateral sclerosis in a Russian population. Zh Nevrol Psikhiatr Im S S Korsakova 2012, 112:42-45. (Article in Russian).
164. Maihöfner C., Probst-Cousin S., Bergmann M., Neuhuber W., Neundörfer B., Heuss D. Expression and localization of cyclooxygenase-1 and -2 in human sporadic amyotrophic lateral sclerosis. Eur. J. Neurosci. 2003, 18:1527-1534.
165. Mandir A.S., Przedborski S., Jackson-Lewis V., Wang Z.Q., Simbulan-Rosenthal C.M., et al. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc. Natl. Acad. Sci. U S A 1999, 96:5774-5779.
166. Marco S., Saura J., Perez-Navarro E., Jose M.M., Tolosa E., Alberch J. Regulation of c-Ret, GFRalpha1, GFRalpha2 in the substantia nigra pars compacta in a rat model of Parkinson's disease. J. Neurobiol. 2002, 52:343-351.
167. Marconi S., Bonaconsa M., Scambi I., Squintani G.M., Rui W., et al. Systemic treatment with adipose-derived mesenchymal stem cells ameliorates clinical and pathological features in the amyotrophic lateral sclerosis murine model. Neuroscience 2013, 248C:333-343.
168. Marwarha G., Rhen T., Schommer T., Ghribi O. The oxysterol 27-hydroxycholesterol regulates α-synuclein and tyrosine hydroxylase expression levels in human neuroblastoma cells through modulation of liver X receptors and estrogen receptors-relevance to Parkinson's disease. J. Neurochem. 2011, 119:1119-1136.
169. Masliah E., Alford M., Mallory M., Rockkenstein E., Moechars D., Van Leuven F. Abnormal transport function in mutant amyloid precursor protein transgenic mice. Exp. Neurol. 2000, 163(2):381-387.
170. Mattammal M.B., Strong R., Lakshmi V.M., Chung H.D., Stephenson A.H. Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's disease. J. Neurochem 1995, 64:1645-1654.
171. McAllister A.K. Neurotrophins and neuronal differentiation in the cental nervous system. Cell Mol. Life Sci. 2001, 58:1054-1060.
172. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996, 47:425-432.
173. McKenzie S., Marley P.D. Caffeine stimulates Ca2+ entry through store-operated channels to activate tyrosine hydroxylase in bovine chromaffin cells. Eur. J. Neurosci. 2002, 15:1485-1492.
174. Mercer J.R., Gray K., Figg N., Kumar S., Bennett M.R. The methyl xanthine caffeine inhibits DNA damage signaling and reactive species and reduces atherosclerosis in ApoE-/- mice. Arterioscler. Thromb. Vasc. Biol. 2012, 32:2461-2467.
175. Merighi S., Benini A., Mirandola P., Gessi S., Varani K., et al. Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. Biochem. Pharmacol. 2006, 72:19-31.
176. Merighi S., Benini A., Mirandola P., Gessi S., Varani K., et al. Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol. Pharmacol. 2007, 72:395-406.
177. Mitsumoto H., Santella R.M., Liu X., Bogdanov M., Zipprich J., et al. Oxidative stress biomarkers in sporadic ALS. Amyotroph. Lateral Scler. 2008, 9:177-183.
178. Miyagishi H., Kosuge Y., Ishige K., Ito Y. Expression of microsomal prostaglandin E synthase-1 in the spinal cord in a transgenic mouse model of amyotrophic lateral sclerosis. J. Pharmacol. Sci. 2012, 118:225-236.
179. Miwa S., Sugimoto N., Yamamoto N., Shirai T., Nishida H., et al. Caffeine induces apoptosis of osteosarcoma cells by inhibiting AKT/mTOR/S6K, NF-κB and MAPK pathways. Anticancer Res. 2012, 32:3643-3649.
180. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., et al. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci. Lett. 1999, 270:45-48.
181. Morcuende S., Muñoz-Hernández R., Benítez-Temiño B., Pastor A.M., de la Cruz R.R. Neuroprotective effects of NGF, BDNF, NT-3 and GDNF on axotomized extraocular motoneurons in neonatal rats. Neuroscience 2013, 250C:31-48.
182. Morel P., Tallineau C., Pontcharraud R., Piriou A., Huguet F. Effects of 4-hydroxynonenal, a lipid peroxidation product, on dopamine transport and Na+/K+ ATPase in rat striatal synaptosomes. Neurochem. Int. 1998, 33:531-540.
183. Moseley A.E., Williams M.T., Schaefer T.L., Bohanan C.S., Neumann J.C., et al. Deficiency in Na,K-ATPase alpha isoform genes alters spatial learning, motor activity, and anxiety in mice. J. Neurosci. 2007, 27:616-626.
184. Moy G.A., McNay E.C. Caffeine prevents weight gain and cognitive impairment caused by a high-fat diet while elevating hippocampal BDNF. Physiol. Behav. 2013, 109:69-74.
185. Mukhopadhyay D., Akbarali H.I. Depletion of (Ca2+)i inhibits hypoxia-induced vascular permeability factor (vascular endothelial growth factor) gene expression. Biochem. Biophys. Res. Commun. 1996, 229:733-738.
186. Munoz L., Ralay Ranaivo H., Roy S.M., Hu W., et al. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J. Neuroinflammation 2007, 4:21.
187. Niessen H.G., Debska-Vielhaber G., Sander K., Angenstein F., Ludolph A.C., et al. Metabolic progression markers of neurodegeneration in the transgenic G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Eur. J. Neurosci. 2007, 25:1669-1677.
188. Numakawa T., Matsumoto T., Numakawa M., Richards M., Yamawaki S., Kunugi H. Protection action of neurotrophic factors and estrogen against oxidative stress-mediated neurodegeneration. J. Toxicol. 2011, 2011:1-12.
189. Ochs G., Penn R.D., York M., Giess R., Beck M., et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron. Disord. 2000, 1:201-206.
190. Ohlin K.E., Francardo V., Lindgren H.S., Sillivan S.E., O'Sullivan S.S., et al. Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. Brain 2011, 134:2339-2357.
191. Ohyama K., Murayama N., Shimizu M., Yamazaki H. Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. Xenobiotica 2013 Jun 18, (Epub ahead of print).
192. Okuno T., Nakatsuji Y., Kumanogoh A., Koguchi K., Moriya M., et al. Induction of cyclooxygenase-2 in reactive glial cells by the CD40 pathway: relevance to amyotrophic lateral sclerosis. J. Neurochem. 2004, 91:404-412.
193. Patel N.S., Mathura V.S., Bachmeier C., Beaulieu-Abdelahad D., Laporte V., et al. Alzheimer's beta-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2. J. Neurochem. 2010, 112:66-76.
194. Peel A.L., Sorscher N., Kim J.Y., Galvan V., Chen S., Bredesen D.E. Tau phosphorylation in Alzheimer's disease: potential involvement of an APP-MAP kinase complex. Neuromol. Med. 2004, 5:205-218.
195. Pehar M., Cassina P., Vargas M.R., Xie Y., Beckman J.S., et al. Modulation of p75-dependent motor neuron death by a small non-peptidyl mimetic of the neurotrophin loop 1 domain. Eur. J. Neurosci. 2006, 24:1575-1580.
196. Pisani A., Martella G., Tscherter A., Costa C., Mercuri N.B., et al. Enhanced sensitivity of DJ-1-deficient dopaminergic neurons to energy metabolism impairment: role of Na+/K+ ATPase. Neurobiol. Dis. 2006, 23:54-60.
197. Plaitakis A., Constantakakis E. Altered metabolism of excitatory amino acids, N-acetyl-aspartate and N-acetyl-aspartyl-glutamate in amyotrophic lateral sclerosis. Brain Res. Bull. 1993, 30:381-386.
198. Prasanthi J.R., Dasari B., Marwarha G., Larson T., Chen X., et al. Caffeine protects against oxidative stress and alzheimer's disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet. Free Radic. Biol. Med. 2010, 49:1212-1220.
199. Prigione A., Isaias I.U., Galbussera A., Begni B., Pezzoli G., Ferrarese C. Increased oxidative stress in lymphocytes from untreated Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15:327-328.
200. Puig B., Gómez-Isla T., Ribé E., Cuadrado M., Torrejón-Escribano B., et al. Expression of stress-activated kinases c-Jun N-terminal kinase (SAPK/JNK-P) and p38 kinase (p38-P), and tau hyperphosphorylation in neurites surrounding betaA plaques in APP Tg2576 mice. Neuropathol. Appl. Neurobiol. 2004, 30:491-502.
201. Pyo H., Jou I., Jung S., Hong S., Joe E. Mitogen-activated protein kinases activated by lipopolysaccharide and β-amyloid in cultured rat microglia. Neuroreport 1998, 9:871-874.
202. Qin W., Ho L., Pompl P.N., Peng Y., Zhao Z., et al. Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity. J. Biol. Chem. 2003, 278:50970-50977.
203. Ramser E.M., Gan K.J., Decker H., Fan E.Y., Suzuki M.M., et al. Amyloid-β oligomers induce tau-independent disruption of BDNF axonal transport via calcineurin activation in cultured hippocampal neurons. Mol. Biol. Cell. 2013, 24:2494-2505.
204. Rantamäki T., Kemppainen S., Autio H., Stavén S., Koivisto H., et al. The impact of BDNF gene deficiency to the memory impairment and brain pathology of APPswe/PS1dE9 mouse model of Alzheimer's disease. PLoS One 2013, 8. e68722.
205. Rathod M.A., Patel D., Das A., Tipparaju S.R., Shinde S.S., Anderson R.F. Inhibition of radical-induced DNA strand breaks by water-soluble constituents of coffee: phenolics and caffeine metabolites. Free Radic. Res. 2013, 47:480-487.
206. Ravi D., Muniyappa H., Das K.C. Caffeine inhibits UV-mediated NF-kappaB activation in A2058 melanoma cells: an ATM-PKCdelta-p38 MAPK-dependent mechanism. Mol. Cell Biochem. 2008, 308:193-200.
207. Ricciotti E., Fitzgerald G.A. Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 2011, 31:986-1000.
208. Rich J.B., Rasmusson D.X., Folstein M.F., Carson K.A., Kawas C., Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995, 45:51-55.
209. Rizzardini M., Mangolini A., Lupi M., Ubezio P., Bendotti C., Cantoni L. Low levels of ALS-linked Cu/Zn superoxide dismutase increase the production of reactive oxygen species and cause mitochondrial damage and death in motor neuron-like cells. J. Neurol. Sci. 2005, 232:95-103.
210. Rothstein J.D., Martin L.J., Kuncl R.W. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N. Engl. J. Med. 1992, 326:1464-1468.
211. Rubach M., Lang R., Hofmann T., Somoza V. Time-dependent component-specific regulation of gastric acid secretion-related proteins by roasted coffee constituents. Ann. N. Y. Acad. Sci. 2008, 1126:310-314.
212. Ryzhov S., McCaleb J.L., Goldstein A.E., Biaggioni I., Feoktistov I. Role of adenosine receptors in the regulation of angiogenic factors and neovascularization in hypoxia. J. Pharmacol. Exp. Ther. 2007, 320:565-572.
213. Saggu H., Cooksey J., Dexter D., Wells F.R., Lees A., Jenner P., Marsden C.D. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. Neurochem 1989, 53:692-697.
214. Sahu S., Kauser H., Ray K., Kishore K., Kumar S., Panjwani U. Caffeine and modafinil promote adult neuronal cell proliferation during 48h of total sleep deprivation in rat dentate gyrus. Exp. Neurol 2013 Aug 3, pii: S0014-4886(13)00238-0. doi:10.1016/j.expneurol.2013.07.021. (Epub ahead of print).
215. Said Ahmed M., Hung W.Y., Zu J.S., Hockberger P., Siddique T. Increased reactive oxygen species in familial amyotrophic lateral sclerosis with mutations in SOD1. J. Neurol. Sci. 2000, 176:88-94.
216. Sallaberry C., Nunes F., Costa M.S., Fioreze G.T., Ardais A.P., et al. Chronic caffeine prevents changes in inhibitory avoidance memory and hippocampal BDNF immunocontent in middle-aged rats. Neuropharmacology 2013, 64:153-159.
217. Salthun-Lassalle B., Hirsch E.C., Wolfart J., Ruberg M., Michel P.P. Rescue of mesencephalic dopaminergic neurons in culture by low-level stimulation of voltage-gated sodium channels. J. Neurosci. 2004, 24:5922-5930.
218. Schultheiss C., Blechert B., Gaertner F.C., Drecoll E., Mueller J. In vivo characterization of endothelial cell activation in a transgenic mouse model of Alzheimer's disease. Angiogenesis 2006, 9:59-65.
219. Scott H.L., Tannenberg A.E., Dodd P.R. Variant forms of neuronal glutamate transporter sites in Alzheimer's disease cerebral cortex. J. Neurochem. 1995, 64(5):2193-2202.
220. Scott H.L., Pow D.V., Tannenberg A.E., Dodd P.R. Aberrant expression of the glutamate transporter excitatory amino acid transporter 1 (EAAT1) in Alzheimer's disease. J. Neurosci. 2002, 22(3):RC206.
221. Seevaratnam R., Raha S., Tarnopolsky M.A., et al. Coffee increases antioxidant enzyme capacity in the brain of male G93A mice, an animal model of amyotrophic lateral sclerosis (ALS) (abstract). FASEB 2009, 23. 109.6.
222. Shin J.H., Lee Y.A., Lee J.K., Lee Y.B., Cho W., et al. Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis. J. Neurochem. 2012, 122:952-961.
223. Shin H.J., Ryu J.H., Kim S.T., Zuo Z., Do S.H. Caffeine-induced inhibition of the activity of glutamate transporter type 3 expressed in Xenopus oocytes. Toxicol. Lett. 2013, 217:143-148.
224. Silverberg J.I., Patel M., Brody N., Jagdeo J. Caffeine protects human skin fibroblasts from acute reactive oxygen species-induced necrosis. J. Drugs Dermatol. 2012, 11:1342-1346.
225. Smach M.A., Charfeddine B., Othman L.B., Lammouchi T., Ltaief A., et al. -1154G/A and -2578C/A polymorphisms of the vascular endothelial growth factor gene in Tunisian Alzheimer patients in relation to beta-amyloid (1-42) and total tau protein. Neurosci. Lett. 2010, 472:139-142.
226. Sonsalla P.K., Wong L.Y., Harris S.L., Richardson J.R., Khobahy I., et al. Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease. Exp. Neurol. 2012, 234:482-487.
227. Soós J.J., Engelhardt J.I., Siklós L., Havas L., Majtényi K. The expression of PARP, NF-kappa B and parvalbumin is increased in Parkinson disease. Neuroreport. 2004, 15:1715-1718.
228. Sun Z.P., Gong L., Huang S.-H., Geng Z., Cheng L., Chen Z.-Y. Intracellular trafficking and secretion of cerebral dopamine neurotrophic factor in neurosecretory cells. J. Neurochem. 2011, 117:121-132.
229. Tanaka H., Nakazawa K. Maternal caffeine ingestion increases the tyrosine level in neonatal rat cerebrum. Biol. Neonate 1990, 57:133-139.
230. Tarkowski E., Issa R., Sjögren M., Wallin A., Blennow K., et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol. Aging 2002, 23:237-243.
231. Teishmann P., Ferger B. Inhibiton of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 2001, 39:167-174.
232. Teishmann P., Tieu K., Choi D.K., Wu D.C., Naini A., et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. U S A 2003, 100:5473-5478.
233. Teraoka M., Nakaso K., Kusumoto C., Katano S., Tajima N., et al. Cytoprotective effect of chlorogenic acid against α-synuclein-related toxicity in catecholaminergic PC12 cells. J. Clin. Biochem. Nutr. 2012, 51:122-127.
234. Tesco G., Latorraca S., Piersanti P., Sorbi S., Piacentii S., Amaducci L. Free radical injury in skin cultured fibroblasts from Alzheimer's disease patients. Ann. NY. Acad. Sci. 1992, 26:49-153.
235. Thal D.R. Excitatory amino acid transporter EAAT-2 in tanglebearing neurons in Alzheimer's disease. Brain Pathol. 2002, 12(4):405-411.
236. Thirumangalakudi L., Samany P.G., Owoso A., Wiskar B., Grammas P. Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease. J. Alzheimers Dis. 2006, 10:111-118.
237. Thomas T., Timmer M., Cesnulevicius K., Hitti E., Kotlyarov A., Gaestel M. MAPKAP kinase 2-deficiency prevents neurons from cell death by reducing neuroinflammation-relevance in a mouse model of Parkinson's disease. J. Neurochem. 2008, 105:2039-2052.
238. Tohgi H., Abe T., Yamazaki K., Murata T., Ishizaki E., Isobe C. Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosis. Neurosci. Lett. 1999, 260:204-206.
239. Tortarolo M., Veglianese P., Calvaresi N., Botturi A., Rossi C., et al. Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. Mol. Cell Neurosci. 2003, 23:180-192.
240. Tovar-y-Romo L.B., Tapia R. Delayed administration of VEGF rescues spinal motor neurons from death with a short effective time frame in excitotoxic experimental models in vivo. ASN Neuro. 2012, 4. pii: e00081.
241. Tsai S.J., Lin C.Y., Mong M.C., Ho M.W., Yin M.C. s-Ethyl Cysteine and s-Propyl Cysteine Alleviate beta-Amyloid Induced Cytotoxicity in Nerve Growth Factor Differentiated PC12 Cells. 2010, 58:7104-7108.
242. Uchino M., Ando Y., Tanaka Y., Nakamura T., Uyama E., et al. Decrease in Cu/Zn- and Mn-superoxide dismutase activities in brain and spinal cord of patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 1994, 127:61-67.
243. Veglianese P., Lo Coco D., Bao Cutrona M., Magnoni R., Pennacchini D., et al. Activation of the p38MAPK cascade is associated with upregulation of TNF alpha receptors in the spinal motor neurons of mouse models of familial ALS. Mol. Cell Neurosci. 2006, 31:218-231.
244. Vila-Luna S., Cabrera-Isidoro S., Vila-Luna L., Juárez-Díaz I., Bata-García J.L., et al. Chronic caffeine consumption prevents cognitive decline from young to middle age in rats, and is associated with increased length, branching, and spine density of basal dendrites in CA1 hippocampal neurons. Neuroscience 2012, 202:384-395.
245. Villa R.F., Arnaboldi R., Ghigini B., Gorini A. Parkinson-like disease by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity in Macaca fascicularis: synaptosomal metabolism and action of dihydroergocriptine. Neurochem. Res. 1994, 19:229-236.
246. Vitvitsky V.M., Garg S.K., Keep R.F., Albin R.L., Banerjee R. Na+ and K+ ion imbalances in Alzheimer's disease. Biochim. Biophys. Acta. 2012, 1822:1671-1681.
247. Voutilainen M.H., Bäck S., Pörsti E., Toppinen L., Lindgren L., et al. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. J. Neurosci. 2009, 29:9651-9659.
248. Wada K., Arai H., Takanashi M., Fukae J., Oizumi H., et al. Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease. Neuroreport. 2006, 17:705-709.
249. Wang H., Shimoji M., Yu S.-W., Dawson T.M., Dawson V.L. Apoptosis inducing factor and PARP-mediated injury in the MPTP mouse model of Parkinson's disease. Ann. N. Y. Acad. Sci. 2003, 991:132-139.
250. Wang L., Dai W., Lu L. Ultraviolet irradiation-induced K+ channel activity involving p53 activation in corneal epithelial cells. Oncogene 2005, 24:3020-3027.
251. Watanabe Y., Watanabe Y., Hamada K., Bommelaer-Bayt M.C., Dray F., et al. Distinct localization of prostaglandin D2, E2, and F2α binding sites in monkey brain. Brain Res. 1989, 478:142-148.
252. Westphalen R.I., Scott H.L., Dodd P.R. Synaptic vesicle transport and synaptic membrane transporter sites in excitatory amino acid nerve terminals in Alzheimer Disease. J. Neural. Transm. 2003, 110(9):1013-1027.
253. Wostyn P., Van Dam D., Audenaert K., De Deyn P.P. Increased cerebrospinal fluid production as a possible mechanism underlying caffeine's protective effect against Alzheimer's disease. Int. J. Alzheimers Dis 2011, 2011:617420.
254. Xiang Z., Ho L., Yemul S., Zhao Z., Qing W., et al. Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expr. 2002, 10:271-278.
255. Yadav S., Gupta S.P., Srivastava G., Srivastava P.K., Singh M.P. Role of secondary mediators in caffeine-mediated neuroprotection in maneb- and paraquat-induced Parkinson's disease phenotype in the mouse. Neurochem. Res. 2012, 37:875-884.
256. Yan Q., Radeke M.J., Matheson C.R., Talvenheimo J., Welcher A.A., Feinstein S.C. Immunochemical localization of TrkB in the central nervous system of the adult rat. J. Comp. Neurol. 1997, 378:135-157.
257. Yang S.P., Bae D.G., Kang H.J., Gwag B.J., Gho Y.S., Chae C.B. Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease. Neurobiol. Aging 2004, 25:283-290.
258. Yanpallewar S.U., Barrick C.A., Buckley H., Becker J., Tessarollo L. Deletion of the BDNF truncated receptor TrkB.T1 delays disease onset in a mouse model of amyotrophic lateral sclerosis. PLoS One 2012, 7:e39946.
259. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNA and proteins in human brain and peripheral organs. Brain Res. 1999, 830:226-236.
260. Yasojima K., Tourtellotte W.W., McGeer E.G., McGeer P.L. Marked increase in cyclooxygenase-2 in ALS spinal cord: implications for therapy. Neurology 2001, 57:952-956.
261. Yasuhara T., Shingo T., Kobayashi K., Takeuchi A., Yano A., et al. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease. Eur. J. Neurosci. 2004, 19:1494-1504.
262. Yasuhara T., Shingo T., Muraoka K., wen Ji Y., Kameda M., et al. The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model. Brain Res. 2005, 1038:1-10.
263. Yokota O., Terada S., Ishizu H., Ishihara T., Nakashima H., et al. Increased expression of neuronal cyclooxygenase-2 in the hippocampus in amyotrophic lateral sclerosis both with and without dementia. Acta Neuropathol. 2004, 107:399-405.
264. Yokoyama H., Kuroiwa H., Tsukada T., Uchida H., Kato H., Araki T. Poly(ADP-ribose) polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. J. Neurosci. Res. 2010, 88:1522-1536.
265. Yuan Q., Zuo X., Jia J. Association between promoter polymorphisms of vascular endothelial growth factor gene and sporadic Alzheimer's disease among northern Chinese Han. Neurosci. Lett. 2009, 457:133-136.
266. Zeidán-Chuliá F., Gelain D.P., Kolling E.A., Rybarczyk-Filho J.L., Ambrosi P., et al. Major components of energy drinks (caffeine, taurine, and guarana) exert cytotoxic effects on human neuronal SH-SY5Y cells by decreasing reactive oxygen species production. Oxid Med Cell Longev 2013, 2013:791795.
267. Zeitlin R., Patel S., Burgess S., Arendash G.W., Echeverria V. Caffeine induces beneficial changes in PKA signaling and JNK and ERK activities in the striatum and cortex of Alzheimer's transgenic mice. Brain Res. 2011, 1417:127-136.
268. Zemlan F.P., Thienhaus O.J., Bosmann H.B. Superoxide dismutase activity in Alzheimer's disease: possible mechanism for paired helical filament formation. Brain Res. 1989, 476:160-162.
269. Zhang L.N., Sun Y.J., Pan S., Li J.X., Qu Y.E., et al. Na+-K+-ATPase, a potent neuroprotective modulator against Alzheimer disease. Fundam. Clin. Pharmacol. 2013, 27:96-103.
270. Zhang Y., Zhang H., Fu Y., Song H., Wang L., et al. VEGF C2578A polymorphism does not contribute to amyotrophic lateral sclerosis susceptibility in sporadic Chinese patients. Amyotroph. Lateral Scler. 2006, 7:119-122.
271. Zhu J.H., Guo F., Shelburne J., Watkins S., Chu C.T. Localization of phosphorylated ERK/MAP kinases to mitochondria and autophagosomes in Lewy body diseases. Brain Pathol 2003, 13:473-481.
272. Zhu J.H., Kulich S.M., Oury T.D., Chu C.T. Cytoplasmic aggregates of phosphorylated extracellular signal-regulated protein kinases in Lewy body diseases. Am. J. Pathol. 2002, 161:2087-2098.
273. Zhu X., Rottkamp C.A., Hartzler A., Sun Z., Takeda A., et al. Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. J. Neurochem. 2001, 79:311-318.
274. Zhu Y., Zhang J., Zeng Y. Overview of Tyrosine Hydroxylase in Parkinson's Disease. CNS Neurol. Disord. Drug Targets 2012, 11:350-358.
275. Zimmerman M.C., Oberley L.W., Flanagan S.W. Mutant SOD1-induced neuronal toxicity is mediated by increased mitochondrial superoxide levels. J. Neurochem. 2007, 102:609-618.
276. Zoia C.P., Tagliabue E., Isella V., et al. Fibroblast glutamate transport in aging and in AD: correlations with disease severity. Neurobiol. Aging 2005, 26(6):825-832.